This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Amarin Corporation plc
Drug Names(s): icosapent ethyl, AMR101, LAX-101; Ethyl Eicosapent, ethyl-eicosapentaenoate; ultra-pure ethyl-EPA; Miraxion, Lyxia (Proposed EU Brand Name, Huntington's)
Vascepa is a semi-synthetic, highly purified derivative of the n-3 fatty acid eicosapentaenoate (EPA).The mechanism of action for Vascepa's impact on lipids is not completely understood. EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased ß-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver (eg by acting as poor substrates for the enzymes responsible for TG synthesis); and increased plasma lipoprotein lipase activity. Gene transcription factors may also be involved in the drug's mechanism, including PPAR, SREBP-1, and ChREBP.
The drug had originally been developed for neurologic applications, where its mechanism of action was thought to involve (1) replenishment of the lipid bi-layer potentially restoring the functions of suffering neurons, (2) reducing the over production of enzymes (phospholipase PLA2) associated with apoptosis and (3) stabilizing mitochondrial integrity of suffering neurons by acting on specific signal transduction pathways and changing cellular energy metabolism. This may prevent or slow progression from neuronal dysfunction to apoptosis.
This product was originally developed in partnership with Laxdale Ltd. In 2004, Amarin completed it's acquisition of Laxdale in an equity financing.
For Miraxion in Huntington's Disease, Amarin has partnered with Scil Biomedicals GmbH (Germany, Austria, France, Benelux), Juste S.A.Q.F. (Spain and Portugal), and Link Pharmaceuticals Ltd (U.K. and Ireland).
Amarin and Kowa
In March 2014, Amarin and Kowa announced an agreement to co-promote Vascepa (icosapent ethyl) capsules, in the United States. Under the agreement, Kowa Pharmaceuticals America will employ its sales force of approximately 250 sales representatives to co-promote Vascepa in the United States augmenting Amarin's approximately 130 sales representatives and more than doubling Amarin's current sales detail frequency through primary and secondary details.
Under the agreement, Kowa will pay for certain incremental costs associated with the use of its sales force that are associated with the...See full deal structure in Biomedtracker
Partners: Kowa Company, Ltd. Eddingpharm
Additional information available to subscribers only: